Effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in HIV late presenters

•Effectiveness of BIC/FTC/TAF was high among HIV late presenters starting ART•In this setting, BIC/FTC/TAF also demonstrated a good safety and tolerability profile•Among people starting ART with AIDS, BIC/FTC/TAF performance was even higher The efficacy of BIC/FTC/TAF in HIV late presenters initiati...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of antimicrobial agents 2024-01, Vol.63 (1), p.107016-107016, Article 107016
Hauptverfasser:	Corona, Diana, Pérez-Valero, Ignacio, Camacho, Angela, Liarte, Ángela Gutiérrez, Montero-Alonso, Marta, Alemán, María Remedios, Ruiz-Seco, Pilar, González, Alexandre Pérez, Riera, Melchor, Jarrin, Inmaculada, Rivero-Juárez, Antonio, Rivero, Antonio
Format:	Artikel
Sprache:	eng
Schlagworte:	Acquired Immunodeficiency Syndrome - drug therapy Adult adults Alanine Amides Anti-HIV Agents - adverse effects antiretroviral agents Coris Drug Combinations Emtricitabine - adverse effects Female Heterocyclic Compounds, 3-Ring HIV Infections - drug therapy Humans Male Piperazines Pyridones regression analysis RNA Tenofovir - analogs & derivatives therapeutics
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	•Effectiveness of BIC/FTC/TAF was high among HIV late presenters starting ART•In this setting, BIC/FTC/TAF also demonstrated a good safety and tolerability profile•Among people starting ART with AIDS, BIC/FTC/TAF performance was even higher The efficacy of BIC/FTC/TAF in HIV late presenters initiating ART has not been sufficiently evaluated. The aim of this study was to assess the effectiveness and tolerability of BIC/FTC/TAF compared to other first-line antiretroviral regimens in treatment-naïve adult individuals from the CoRIS Cohort starting ART with CD4 counts
ISSN:	0924-8579 1872-7913
DOI:	10.1016/j.ijantimicag.2023.107016